Login to Your Account



XOMA Plans Public Offering Of 9M Shares Following Panel Nod

By Aaron Lorenzo


Friday, September 12, 2003
Two days after an FDA advisory panel recommended approval of its partnered psoriasis drug Raptiva, XOMA Ltd. disclosed plans for a public offering of 9 million common shares. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription